On October 23, 2023, IMPACT Therapeutics presented preliminary clinical data on IMP7068, a WEE1 inhibitor, at the ESMO Congress 2023 in an oral presentation.

Highlights of mini oral Presentation Information (refer to ESMO2023 for more details):

Mini oral ID: 662MO

Title: Phase 1, Multi-Center, Dose-escalation and Dose-expansion Study of IMP7068, a WEE1 Inhibitor, in Patients with Advanced Solid Tumors

Session：Developmental therapeutics

• IMP7068 is a potent and selective WEE1 inhibitor. The ongoing phase I study comprises dose escalation and dose expansion stages. The dose escalation phase evaluated the safety and preliminary antitumor activity of IMP7068 in 54 patients with advanced solid tumors. IMP7068 demonstrated good tolerability and manageable safety profile, with promising efficacy signals observed in patients with uterine serous cancer. The recommended phase II dose (RP2D) for monotherapy with IMP7068 was announced at ESMO Congress 2023. The expansion stage is currently ongoing.

“We are pleased to share the progress of IMP7068 in phase I study at this year's ESMO Annual Meeting. As a novel WEE1 inhibitor, IMP7068 has shown encouraging efficacy and safety signals in advanced solid tumors. The data reported at this ESMO show the RP2D and initial efficacy of IMP7068, which we will further validate in an expansion phase and explore the efficacy and safety of IMP7068 in specific tumors”, said Dr. Chih-Yi Hsieh, Chief Medical Officer of IMPACT Therapeutics.

About IMP7068

IMP7068, independently developed by IMPACT Therapeutics, is a potent and novel WEE1 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity. The early-phase trials demonstrated the promising anti-tumor effect of IMP7068.

About IMPACT Therapeutics

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064)，and PARP1 selective inhibitor (IMP1734, in collaboration with Eikon Therapeutics), as well as other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/IMP4297), has successfully completed Phase III pivotal trial in ovarian cancer first-line maintenance (FLAMES study) setting with best-in-class efficacy and safety profile. Based on the results of the FLAMES study, The Senaparib New Drug Application (NDA) has been accepted for review by the National Medical Products Administration (NMPA) of China. WEE1 inhibitor IMP7068 and ATR inhibitor IMP9064 is undergoing global Phase I clinical study. PARP1 selective inhibitor IMP1734 has obtained IND clearance from FDA.